Jason Westin, MD FACP FASCO

@Lymphoma_Doc

Professor @MDAndersonNews, Lead of Lymphoma/Myeloma Service Line, Director of Clinical Research, Section Chief of Aggressive/Indolent Lymphomas, Opinions mine

Houston, TX faculty.mdanderson.org/profiles/jason… Joined January 2013

3.3K Following 7.6K Followers 8.2K Posts

Latest posts 5

Pinned post

Jason Westin, MD FACP FASCO @Lymphoma_Doc Apr 17, 2024

I am so honored to receive the @ASCO Advocate of the Year award. Engaging with advocacy is such an important way to support our patients. #ASCOAdvocacySummit

ASCO @ASCO Apr 17, 2024

“If we're not advocating…fighting against #drugshortages & for NCI funding & the CONNECT for Health Act, others are advocating the other direction...What you're doing here really matters,” Advocate of the Year @lymphoma_doc. Congrats! brnw.ch/21wISP5 #ASCOAdvocacySummit

View quoted post on X

Jason Westin, MD FACP FASCO @Lymphoma_Doc Sep 3

Join us to make a lasting impact against cancer. Through her patient care, research, & leadership, @rachnatshroff has already changed thousands of lives. Now, it’s our turn to ensure her legacy continues for years to come. @ConquerCancerFd @ASCO
support.conquer.org/p2p/site/17Smz…

support.conquer.org Conquer Cancer, the ASCO Foundation | Rachna T. Shroff HONORING DR. RACHNA SHROFF'S EXTRAORDINARY LEGACY Help carry her life’s work forward with a gift to support the future of cancer research and care.

Jason Westin, MD FACP FASCO @Lymphoma_Doc Feb 6

Outstanding presentation by @drsairahahmed at #Tandem26 showing promising data with liso-cel in Follicular lymphoma now at 3+ years of follow up. @ASTCT @CIBMTR #tandem2026

Jason Westin, MD FACP FASCO @Lymphoma_Doc Oct 3, 2025

The SUNMO trial manuscript is now published at @JCO_ASCO! Mosun-Pola is superior to RGemOx in patients with ref/rel LBCL with 3X progression free survival and 2x complete response rates. Only 4% had CRS more than a fever. #lymsm
@elizabeth_budde
ascopubs.org/doi/10.1200/JC…

ascopubs.org Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell... PURPOSEPrognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell–engaging...

Jason Westin, MD FACP FASCO @Lymphoma_Doc Aug 20, 2025

Grateful for the opportunity to serve on the @ASCO Board of Directors. Looking forward to contributing to the mission of conquering cancer through research, education, and promotion of the highest quality patient care.
connection.asco.org/do/asco-announ…

connection.asco.org ASCO Announces Dr. Jason Westin as New Member of Society Board of Directors ASCO is pleased to welcome Dr. Jason Westin to the Society Board of Directors. Dr. Westin is filling a seat vacated by Dr. Nathan Pennell, who stepped down after accepting a new employment opportunity